At the beginning of March Laboratory of Allergology has transferred to the production 12 new allergens, including 5 food allergens, 3 moulds, 4 different allergens from epithelia, trees, weeds and other allergens groups and 1 weed mix.

The microbiology laboratory began working in early December after licensing for carrying out activities in using of human & animal pathogens of infectious diseases and genetically modified organisms, the 3^rd and 4^th degrees of potential danger, in closed systems.

9th November 2016 the European Patent Office granted the patent "Biotransplant for cellular therapy based on mesenchymal bone marrow stem сells for "Trans-Technologies" Ltd (Alkor Bio Group of Companies)". The patent application describes derivation of culture of human mesenchymal stem cells from bone marrow and using them for production of corresponding biotransplant. The invention refers to the field of cellular therapy and tissue engineering and may potentially be used, for instance, in treatment of various ischaemic diseases. The invention considered new indeed, that is especially remarkable due to the tough competition in the human stem cell research field in European Union.

Alkor Bio Group's Laboratory of Allergology completed the development and transferred to the production 39 new allergens for in vitro allergen diagnostics. Thus, today Alkor Bio Group produces 670 allergens, 125 of them were developed in 2016.

At the 3^rd Congress “Innovative practice: Science and Business” from December 7, 2016 the winners of 5^th Russia’s fast-growing high-tech companies national rating “Techup-2016” were announced.

At the beginning of December Alkor Bio Group has obtained CE-mark certificate for the new kit “TreponemaEIA-Total Antibodies”.